Compare Marsh & McLennan Companies, Inc. (MRSH) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marsh & McLennan Companies, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Marsh & McLennan Companies, Inc. trades at $191.32 (market cap $91.27B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: Marsh & McLennan Companies, Inc. pays a 2.07% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Marsh & McLennan Companies, Inc. nearer its low. Which is the better fit depends on your goals.
| MRSH | XBI | |
|---|---|---|
Market Cap | $91.27B | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $211.21 | $164.28 |
52-Week Low | $157.32 | $86.92 |
Enterprise Value | $111.95B | — |
Dividend Yield | 2.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marsh & McLennan (MRSH) trades at $188.81, down 1.04% today, but maintains a bullish technical trend with strong fundamentals. The company reported Q2 2026 EPS of $2.96, beating estimates, and has consistently exceeded earnings expectations. Revenue growth remains solid at 6% in Q2 2026, driven by risk and consulting services. Recent acquisitions, like the planned purchase of Accel Holdings, aim to expand its Midwest insurance reach.
The outlook is positive with a consensus price target of $202.89, suggesting 7.5% upside. Risks include margin pressure from rising expenses and soft P&C pricing. Analyst sentiment is mixed with 30.3% buy ratings but 66.7% hold, indicating cautious optimism. Institutional activity shows new positions by Ashton Thomas Securities and Bank of Nova Scotia, supporting long-term growth prospects.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
